Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 12/20 | 0.41 |
| ▸ | JAK1 | P23458 | 12/20 | 0.41 |
| ▸ | JAK3 | P52333 | 12/20 | 0.41 |
| ▸ | TYK2 | P29597 | 10/20 | 0.41 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.33 |
| ▸ | PDE2A | O00408 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | ALPL | P05186 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12005139 | 0.88 | JAK2 (0.41) | JAK2JAK1JAK3TYK2MAPK1 | |
| SCHEMBL1662234 | 0.79 | JAK2 (0.42) | JAK2JAK1JAK3TYK2ADORA1 | |
| SCHEMBL1662357 | 0.78 | CDK2 (0.43) | JAK2JAK1JAK3TYK2ADORA1 | |
| SCHEMBL1665155 | 0.77 | JAK2 (0.42) | JAK2JAK1JAK3TYK2ADORA1 | |
| SCHEMBL1662463 | 0.76 | JAK2 (0.41) | JAK2JAK1JAK3TYK2ADORA1 | |
| SCHEMBL1662420 | 0.73 | DAO (0.47) | JAK2JAK1JAK3TYK2 | |
| SCHEMBL1662814 | 0.73 | JAK2 (0.53) | JAK2JAK1JAK3TYK2 | |
| SCHEMBL1662427 | 0.71 | JAK2 (0.41) | JAK2JAK1JAK3TYK2ADORA1 | |
| Hydrochloric Acid SCHEMBL4715431 | 0.66 | JAK1 (0.63) | JAK2JAK1JAK3TYK2 | |
| SCHEMBL1662425 | 0.65 | CYP2D6 (0.37) | JAK2JAK1JAK3TYK2ADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120220624-A1 | PYRAZOLO [3,4-B] PYRIDIN-4-ONE KINASE INHIBITORS | MERCK SHARP & DOHME CORP. | 2012-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120220624-A1 | PYRAZOLO [3,4-B] PYRIDIN-4-ONE KINASE INHIBITORS | CDK1, CDK5, TTBK1 | JAK2 799/4885JAK1 285/4885JAK3 402/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.